MedPath

PRECISION MOLECULAR IMAGING & THERANOSTICS PTY LTD

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

2 Phases

Early Phase 1:1
Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Early Phase 1
1 (50.0%)
Phase 1
1 (50.0%)

68Ga-NTA-476 Imaging in Prostate Cancer

Early Phase 1
Not yet recruiting
Conditions
Prostate Cancer
Interventions
First Posted Date
2024-07-25
Last Posted Date
2024-07-25
Lead Sponsor
Melbourne Theranostic Innovation Centre
Target Recruit Count
10
Registration Number
NCT06520449

News

First Patient Dosed in Pioneering ZOLAR Trial of TLX300-CDx for Advanced Soft Tissue Sarcoma

Telix Pharmaceuticals has dosed the first patient in its Phase 1 ZOLAR trial evaluating TLX300-CDx (89Zr-olaratumab) in patients with advanced soft tissue sarcoma at Melbourne Theranostic Innovation Centre.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.